Celldex Therapeutics enters the post-earnings stretch with a striking split: short sellers are unwinding at pace while the analyst community shifts decisively more constructive, yet the stock is still down 5.5% on the week.
The short-interest unwind is the week's defining move. SI % FF has fallen from above 12.5% in mid-April to 10.2% now — a drop of more than two percentage points in under a month. The sharpest leg came last week, with estimated short positions declining roughly 11% in five sessions. That is a meaningful retreat from what had been a persistent short thesis. Borrow conditions tell the same story: cost to borrow has halved since early April when it briefly touched 0.73%, and now runs at 0.45%. Availability remains loose — utilization has eased from above 7% in April to 3.5% today, well below the 52-week peak of 16%, suggesting there is no squeeze dynamic at work here. Shorts are leaving voluntarily, not being forced out.
The catalyst is apparent in the analyst tape. Wells Fargo raised its target to $54 today, maintaining Overweight — a 42% lift from the prior $38 level. That follows Barclays' target hike to $48 from $45 last Thursday. More striking is the Barclays arc: the same analyst who initiated coverage at Underweight with a $25 target in October 2025 upgraded to Overweight at $45 in late April, and has now raised again within weeks. Goldman Sachs sits at Neutral with a $34 target, the lone hold-out among the recent movers. The consensus mean price target now stands at $57.50 — nearly 80% above the current price of $32. That gap is wide even by biotech standards, but it reflects the directional shift rather than precision forecasting. The stock carries a very high analyst recommendation divergence score, ranked in the 92nd percentile, meaning the spread of views remains unusually wide.
The bull case centres on barzolvolimab. Phase II data in chronic spontaneous urticaria has shown durable results, and Phase III trials are advancing. A 44-week data readout from the cold-induced urticaria indication is the near-term clinical watchpoint. The bear case is straightforward: this is a pre-revenue clinical-stage company burning cash, with a negative P/E and negative EV/EBITDA. The price-to-book stands at 4.5x, declining modestly over the past month. EPS momentum over the last 30 days ranks in the 23rd percentile — the Q1 print missed by $0.03 per share and triggered a 1.2% one-day decline on May 7, though the stock had largely priced in the miss.
Options positioning has tilted more cautious. The put/call ratio climbed to 1.29, above its 20-day average of 1.06 by roughly one standard deviation. That is not extreme — the 52-week range runs from 0.20 to 3.58 — but the drift higher coincides with the post-earnings slide. Before late April, the PCR was running below 0.80, reflecting the optimism that followed the February earnings release, when the stock surged 23% in a single day. The current setup is more balanced: options traders are hedging more, but not at panic levels.
On the ownership side, Wellington Management is the largest holder with just over 10% of shares, having added 2.3 million shares in the first quarter. State Street added 556,000 shares as recently as April, and Fidelity and Vanguard both added modestly. The institutional base is broadly stable and adding — a floor that typically matters more during drawdowns. Insider data is stale beyond 90 days, limiting its read-through this week.
Next on the calendar is a Q2 earnings event on June 25. Given the recent earnings history — a 23% gain on February 25 and a 7.9% gain in the November cycle — the question for the next print will be less about the quarterly loss and more about the clinical milestone update on barzolvolimab and whether the 44-week CIndU data carries the kind of durability signal that accelerates Phase III timelines.
See the live data behind this article on ORTEX.
Open CLDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
